Fresenius to buy Akorn for $4.3B

Posted online April 25, 2017 | 11:28 am

Germany’s Fresenius SE agreed to buy Illinois-based generic drugmaker Akorn Inc. for $4.3 billion.

Including debt, the Akorn deal has an enterprise value of $4.75 billion.

Separately, Fresenius announced plans to buy Merck KGaA’s portfolio of biosimilars, which are copycat versions of complex biotechnology drugs, for $184.7 million, plus licensing fees.

Read more from Bloomberg.

[[In-content Ad]]

Comments

No comments on this story |

Please log in to add your comment

Burger restaurant opens at Vib hotel

Editors' Pick

Open for Business: Yallternative Eats

A food truck that launched last year rebranded and moved to Metro Eats; automotive repair business Mitchem Tire Co. expanded its Christian County presence; and O’Reilly Build LLC was acquired.

Most Read